Astellas Pharma Inc.
Notice Regarding Continuation of Performance-Linked Stock Compensation System
Astellas Pharma has decided the details of the incentive plan to be implemented in FY2026, specifying target participants, trust period, and method of stock acquisition. The trust period runs from May 21, 2026, to the end of August 2029, with a trust amount of approximately ¥1.116 billion. The company will continue to operate its incentive system to enhance corporate value.
Key Figures
- Trust amount: ¥1,116 million (planned)
- Trust period: From May 21, 2026 (planned) to the end of August 2029 (planned)
- Method of stock acquisition: Acquired from the stock market
AI要約
Future Outlook and Impact
Astellas Pharma continues to aim to enhance management and employee motivation for increasing corporate value through its incentive system. The continuation of the system aims to improve long-term shareholder value and ensure transparency and fairness of the stock compensation scheme. The company will closely monitor the operation of the system and the results of trust fund management to ensure proper system administration.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
